

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The health and coping strategies of nursing home residents and their relatives during the COVID-19 pandemic: a mixed-methods study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059262
Article Type:	Protocol
Date Submitted by the Author:	13-Nov-2021
Complete List of Authors:	Ortoleva Bucher, Claudia; University of Applied Sciences Western Switzerland La Source School of Nursing Abt, Maryline; University of Applied Sciences Western Switzerland La Source School of Nursing Berthoud, Laurent; University of Applied Sciences Western Switzerland La Source School of Nursing Cohen, Christine; University of Applied Sciences Western Switzerland La Source School of Nursing
Keywords:	COVID-19, MENTAL HEALTH, GENERAL MEDICINE (see Internal Medicine)

SCHOLARONE™
Manuscripts

1
2
3
4 Title Page
5

- 6
7 a) **Title:** The health and coping strategies of nursing home residents and their relatives during
8 the COVID-19 pandemic: a mixed-methods study protocol
9
10
11 b) **All authors' full names:** Claudia ORTOLEVA BUCHER, Maryline ABT, Laurent BERTHOUD,
12 Christine COHEN
13
14
15 c) **Corresponding author:** Claudia Ortoleva Bucher, HES-SO University of Applied Sciences and
16 Arts Western Switzerland, La Source School of Nursing Sciences, Avenue Vinet 30, 1004
17 Lausanne, Switzerland. ORCID ID: 0000-0002-8411-4181, E-mail:
18 c.ortolevabucher@ecolelasource.ch, Phone: +41 21 556 40 42
19
20
21
22 d) Claudia ORTOLEVA BUCHER: La Source School of Nursing Sciences, HES-SO University of
23 Applied Sciences and Arts Western Switzerland, La Source School of Nursing Sciences,
24 Avenue Vinet 30, 1004 Lausanne, Switzerland. ORCID ID: 0000-0002-8411-4181
25
26
27 Maryline ABT: La Source School of Nursing Sciences HES-SO University of Applied Sciences and
28 Arts Western Switzerland, La Source School of Nursing Sciences, Avenue Vinet 30, 1004
29 Lausanne, Switzerland. ORCID ID: 0000-0002-8867-951
30
31
32
33 Laurent BERTHOUD: La Source School of Nursing Sciences, HES-SO University of Applied
34 Sciences and Arts Western Switzerland, La Source School of Nursing Sciences, Avenue Vinet
35 30, 1004 Lausanne, Switzerland. ORCID ID: [0000-0002-6575-9101](https://orcid.org/0000-0002-6575-9101)
36
37
38
39 Christine COHEN: La Source School of Nursing Sciences, HES-SO University of Applied Sciences
40 and Arts Western Switzerland, La Source School of Nursing Sciences, Avenue Vinet 30, 1004
41 Lausanne, Switzerland. ORCID ID: [0000-0001-8681-0933](https://orcid.org/0000-0001-8681-0933)
42
43
44 e) **Keywords:** coping, nursing home residents, nursing home relatives, stressors, mixed-
45 methods, confinement measures, COVID-19 pandemic.
46
47
48 f) **No. of words:** 4287
49

50
51 La Source School of Nursing, University of Applied Sciences and Arts Western Switzerland
52 (HES-SO)

53
54 Avenue Vinet 30

55
56
57
58
59 Lausanne, CH 1004
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 **Title:** The health and coping strategies of nursing home residents and their relatives during the
3 COVID-19 pandemic: a mixed-methods study protocol
4

5
6
7
8 **Introduction:** The COVID-19 pandemic hit older adults particularly hard, especially those living in
9 nursing. The present study's primary aim is to quantify the states of physical and mental health of
10 nursing home residents and their relatives following the implementation of the exceptional
11 confinement measures. The secondary aim is to explore the lived experiences of the stressors
12 perceived by older adults and their relatives, as well as the support strategies implemented by health
13 professionals and their results.
14

15
16 **Methods and analysis:**

17 We chose a mixed-methods (quantitative/qualitative) study to best deliver a profound understanding
18 of this phenomenon.
19

20
21 Quantitative phase: Participants are asked to complete several questionnaires. The study population
22 includes all the nursing home residents in four French-speaking cantons of Switzerland (and their
23 relatives) who are living through the COVID-19 pandemic. Descriptive statistics will be calculated for
24 the scores of the GHQ-12, IES-6, PSS, Brief Cope, PTGI-SP, WHOQOL-BREF and WHOQOL-OLD scales.
25 Correlational analyses will be considered.
26

27 Qualitative phase: Data are collected from several sources (individual semi-structured interviews,
28 focus groups, field notes). Interviews are planned with about 12 representatives of each group of
29 participants (residents and relatives). Two focus groups made up of healthcare professionals will be
30 constituted to explore their perceptions of residents' and relatives' lived experiences of stressors, the
31 coping strategies those two groups implemented to deal with them. The interviews and focus groups
32 will be subjected to a thematic contents analysis.
33

34
35 Integrating the quantitative and qualitative data will take place jointly with data interpretation.
36

37 **Ethics and dissemination:** This project was approved by the Human Research Ethics Committee of the
38 Canton of Vaud on 14 December 2020 (Project-ID: 2020-02397). The prior written informed consent
39 of the study subjects is collected by a member of the research team before data collection.
40

41
42
43
44
45 **Trial registration: ISRCTN12345167**
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STUDY STRENGTHS AND LIMITATIONS

- This study explores the lived experiences of nursing home residents and their relatives during the COVID-19 pandemic.
- It will enable an analysis of the coping strategies adopted by nursing home residents and their relatives and the strategies implemented by their healthcare and support professionals.
- Using a mixed-methods design facilitates a deep investigation of lived experiences.
- Using a transversal methodology does not enable an investigation of changes over time.
- The study begins roughly one year after the start of the COVID-19 pandemic, and numerous residents living in our participating nursing homes have since died.

INTRODUCTION

In China, in December 2019, the COVID-19 pandemic was just beginning—the latest in a series of epidemics that humanity has had to face over the last 100 years. Indeed, just this century, we have had SARS in 2002–2003, H1N1 in 2009 and MERS in 2012 (1). Lived experiences of these epidemics have affected communities' physical and psychological health (2). The general population, including those not infected by the disease itself, still bears psychological scars (3–6). Older adults within that general population were also affected (5). Zurich University of Applied Sciences and the University of Zurich launched a study entitled "COVID-19 Social Monitor" among home-dwelling older adults, and its initial findings revealed that 41% of those questioned estimated that their overall quality of life (QoL) had deteriorated relative to before the pandemic, 50% presented with symptoms of psychological stress and exhaustion, and 9% suffered from loneliness (7). We sought to examine these issues among the residents of nursing homes caring for the very oldest people—those who often present with several comorbidities. Although this population has been the most vulnerable to the last 20 years' epidemics, the scientific research focus on it has been small (8). COVID-19 badly affected nursing homes in many countries when they became the centres of epidemic outbreaks (9). To date, half the deaths due to COVID-19 in French-speaking Switzerland have been in nursing homes (10). Drastic measures were taken to stem this grim tide, including physical isolation, one-way walking systems to reduce meetings, and bans on visiting (11).

Brooke and Jackson (12) have denounced the ageism that has clearly entered into public discourse since the beginning of the COVID-19 pandemic, mentioning some shocking reports about how nursing home residents were almost abandoned (13). Expressions of flagrant ageism have appeared and been rapidly amplified since the beginning of the pandemic, for example, under the hashtag #BoomerRemover, a nickname given to COVID-19. The coronavirus caused a resurgence of intergenerational conflict (14). Although some concerns were expressed about how older adults were being represented or positioned in this discourse, it was also often accompanied by unappreciative and disparaging language (15). Online discussions and comments about care rationing were also recurrent subjects of media attention, going so far as to suggest that the death of an old person was less important than that of a young one (16).

The people stigmatised and discriminated against (both COVID-19 survivors and members of the general population) have reported their feelings of abandonment and isolation (17–19). Survivors have declared feeling abandoned by their communities and kept at a distance from their caregivers by the personal protective equipment that has become so ubiquitous (17–19). Quarantine or isolation was previously an uncommon, disagreeable experience involving separation from one's family and friends and a total break from daily routines. Isolation is known to cause psychosocial problems and could affect any human being. Those already known to be vulnerable to them and particularly at risk of psychological harm include children and adolescents, nursing home residents, minority groups, people from socioeconomically disadvantaged groups, women and individuals suffering from pre-existing mental disorders (20). Even though people who are isolated or in quarantine understand the necessity of those measures, they nevertheless feel a sense of abandonment that can persist beyond those periods (21). Social isolation in association with quarantine can affect the state of mental health of previously healthy people. They can present with symptoms linked to acute stress disorders, irritability, sleeping disorders, emotional distress, mood disorders, depressive symptoms, fear and panic, anxiety, frustration and the boredom of solitude (22–26). Furthermore, longer periods of confinement have been associated with more severe symptoms of post-traumatic stress disorder, avoidance behaviours and greater feelings of anger (25). The longest periods of quarantine are particularly associated with increased symptoms of post-traumatic stress disorder, which may indicate that quarantine itself is lived as a traumatic experience (23).

1
2 Because of their inherent organisational characteristics and the strict confinement measures imposed
3 on them during the pandemic, long-term residential care facilities generated stressors among their
4 residents that the general population did not feel: isolation and solitude had particularly negative
5 impacts on residents' physical and mental health, including their risks of anxiety, depression, cognitive
6 dysfunction, heart diseases and mortality (27, 28). It should be noted that stress does not only lead to
7 negative impacts. The strategies and processes put in place to cope with these enable individuals to
8 change, adapt and appreciate their results. People can thus find the resources they need, experiment
9 with different positive changes and grow out of their trauma (17, 21, 29-31).

11
12 To the best of our knowledge, nursing home residents and their relatives have yet to be the subjects
13 of much scientific research despite their clear vulnerabilities in the face of the pandemic. The American
14 Association for Geriatric Psychiatry has announced that it will support the scientific and healthcare
15 communities worldwide in order to help plan effective care for nursing home residents, avoid the risks
16 of this population becoming marginalised in political discussions surrounding COVID-19 and produce
17 the greatest amount of valid, evidence-based data with which to orient more effective care during this
18 critical period (8). This clear positioning by one of the world's most active professional associations in
19 the field of care home residents' mental health shows how urgent the need is for more knowledge in
20 this domain.

22
23 Our research is framed within the concepts and processes of the Neuman systems model (2011), which
24 takes a holistic perspective oriented towards well-being. The model conceptualises the individual as
25 an open system subject to stressors that may or may not lead to damage to their health. Stressors are
26 considered neutral a priori, and their positive effects (eustress) or negative effects (distress) are largely
27 dependent on a person's perceptions and their capacity to face up to that stress. Following the
28 prolonged lockdown implemented towards the beginning of the COVID-19 pandemic, older adult
29 residents in nursing homes and their relatives were exposed to a variety of stressors susceptible of
30 destabilising them.

32
33 It is also essential to study the perceptions that healthcare and support professionals have of the lived
34 experiences of nursing home residents and their relatives. Indeed, they have a special relationship with
35 them. Thanks to these relationships, they are crucial to initiating any in-depth evaluation of the effects
36 of the internal and external stressors to which residents are exposed and their capacity for coping with
37 them (32, 33).

39
40 The present study will attempt to evaluate the physical and mental health statuses of nursing home
41 residents and their relatives following the exceptional lockdown measures implemented due to the
42 COVID-19 epidemic. The research objectives are the following:

- 43 - Describe the level of symptoms (post-traumatic stress, anxiety, depression, social
44 maladjustment and somatic disorders), post-traumatic growth and QoL of nursing home
45 residents and their relatives after the COVID-19 pandemic.
 - 46 - Describe the strategies implemented (by residents and relatives) for coping with the COVID-
47 19 pandemic.
 - 48 - Explore residents and relatives lived experiences of their perceived stressors during the COVID-
49 19 pandemic and their links to any potential physical or mental health symptoms, post-
50 traumatic growth and QoL.
 - 51 - Explore which stressors healthcare and support professionals observed affecting residents and
52 their relatives.
 - 53 - Explore which strategies healthcare and support professionals implemented to support
54 residents and their relatives and help them cope with the stressors they faced during the
55 COVID-19 pandemic, including their results.
- 56
57
58
59
60

METHODS AND ANALYSIS

Study design overview

This study is based on a mixed-methods (quantitative/qualitative) design chosen because there are very few available data on nursing home residents. The variety and complexity of residents' health statuses, the different living environments in their nursing homes and the changing relationships with their relatives made us hypothesise that findings that might seem obvious or natural in Switzerland's general population might not be readily transferable to our subjects without significant adjustments. Using a mixed-methods study design would help us develop a deeper understanding of our phenomenon of interest (34, 35).

Quantitative phase

Data collection

We use a paper questionnaire format to explore and respond to our research questions. We ensured that validated French-language versions of the questionnaires selected had the necessary psychometric qualities and that they were appropriate with regards to our study's concepts, thus safeguarding the validity of our recorded data.

Data collected from our participating nursing home residents come from several sources (36). In order to describe our sample, we decided to measure residents' sociodemographic variables (age, sex, marital status, year of entry into the nursing home) as well as those of their relatives (age, sex, marital status, relationship with the nursing home resident, current nature and frequency of contact with the resident).

We also collect data on the lockdown measures implemented in the participating older adults' nursing homes (residents isolated in their rooms, availability of communication tools such as tablet computers, preparation of screened visiting rooms, etc.).

Participants

Our potential study population includes all nursing home residents aged 65 years old or more and their relatives (spouses, children, siblings, friends, cousins) living through the COVID-19 experience in one of Switzerland's four majority French-speaking cantons.

For residents, inclusion criteria are: being over 65 years old, being able to discern and being able to speak and understand French; and exclusion criteria are: the presence of major irreversible neurocognitive disorders. For relatives, inclusion criteria are: being able to discern and being able to speak and understand French; and there is no exclusion criteria. For healthcare professionals are: working on the unit for more than 3 months and to have a care relationship with the residents and the family member; and exclusion criteria are: being a temporary worker or a student.

Sample and recruitment

The recruitment procedure for our study's quantitative arm involves nursing home residents and their relatives. We aim for a sample of 150 residents and 150 relatives. This is done via the intermediary of care unit heads who identify residents susceptible of participating in our study because they fulfil our inclusion criteria. Investigators then visit the nursing homes and speak individually to potential subjects to inform them about the study. Residents are given time to reflect and to declare their consent to participate. A researcher then returns to sit with them while they complete their questionnaires. Relatives complete the questionnaires on their own.

Measurements

We use the following questionnaires to help us answer our research questions:

- The **General Health Questionnaire (GHQ-12, 12 items)** for detecting mental disorders in the general population (Cronbach's alpha: 0.91) (61).
- The **WHOQOL-BREF scale (26 items)** for relatives to establish their subjective QoL (Cronbach's alpha: ≥ 0.65).
- The **WHOQOL-OLD scale (24 items)** for residents to evaluate their QoL (Cronbach's alpha: 0.72–0.83) (37).
- The **Impact of Event Scale 6 (IES-6, 6 items)** for measuring the symptoms associated with post-traumatic stress in individuals who have undergone a traumatic event (Cronbach's alpha: 0.95) (38).
- The **Post-traumatic Growth Inventory (PTGI-SP, 10 items)** for evaluating post-traumatic growth, i.e. positive, lived psychological change following a traumatic event (Cronbach's alpha: 0.90) (39).
- The **Perceived Stress Scale (PSS, 14 items)** for evaluating perceptions of stress (Cronbach's alpha: 0.74) (40).
- The **Brief Cope (28 items)** for evaluating coping strategies (Cronbach's alpha: 0.50–0.90) (41).

Analysis procedures for quantitative data

Data will be examined using Stata® statistical software, version 16. Data will first be cleaned, and if more than 10% of responses are missing from a particular scale, then that subject's observations will be discarded. Total scores and subscale scores for each questionnaire will be calculated following their authors' particular recommendations. For categorical or discrete variables, frequencies, percentages and modes will be calculated. For continuous variables, means, medians, standard deviations and interquartile ranges will be calculated. Skewness and kurtosis coefficients will be calculated to evaluate distributions and their normality. We will calculate descriptive statistics for the total scale scores and subscale scores of the GHQ-12, IES-6, PSS, Brief Cope, PTGI-SP, WHOQOL-BREF and WHOQOL-OLD scales. Finally, we will perform correlational analyses between the subscale scores for the GHQ-12, IES-6, PTGI-SP, WHOQOL-BREF and WHOQOL-OLD scales and the subscales scores of the Brief Cope scale.

Sociodemographic variables will be analysed using descriptive statistics depending on the variable measured.

Qualitative phase

Data collection

Qualitative data are collected from a number of sources (36):

- Individual, semi-structured, 20–30-minute interviews are carried out with **residents**, with the aid of an interview guide, to explore their perceptions of their lived experiences of stressors, the coping strategies that they implemented to deal with them and the results they obtained.
- Individual, semi-structured, 30–40-minute interviews are carried out with **relatives**, with the aid of an interview guide, to explore their perceptions of their lived experiences of stressors, the coping strategies that they implemented to deal with them and the results they obtained.
- Two 60–90-minute focus groups will be run with **nursing home professionals**, with the aid of an interview guide, to explore their perceptions of residents' and relatives' lived experiences of stressors, the coping strategies those two groups implemented to deal with them and the results they obtained.

- The research team keeps field notes about visits to nursing homes and during interviews. In particular, this information includes investigators' notes on participants' behaviours.

Participants

The nursing home residents and their relatives selected for this qualitative data collection phase are subject to the same selection criteria used in the quantitative data collection phase. The inclusion criteria for nursing home professionals are to have worked in the unit for at least three months and to have regular contact with both residents and their relatives. Exclusion criteria include being a temporary employee, a part-time employee, or a student.

Sample and recruitment

Participants are selected using purposive sampling to ensure representativity across several variables (severity of symptoms, post-traumatic growth, QoL, varied coping strategies). Interviews are planned with about 12 representatives of each group of participants (residents and relatives) or until data saturation.

Two discussion groups made up of healthcare professionals will be constituted to explore their perceptions of residents' and relatives' lived experiences of stressors, the coping strategies those two groups implemented to deal with them and what those strategies' results were. All the healthcare professionals in our partner nursing homes will be invited to participate.

Analysis procedures for qualitative data

Data analysis began as soon as data collection began and continues iteratively. Interviews are to be recorded. All interviews will be audio-recorded in full and transcribed verbatim into a Word 365 ProPlus® file. Investigators' field notes will also be added to that Word 365 ProPlus® file. Data will subsequently undergo a thematic contents analysis that will enable the investigators to identify pertinent information, relationships and meanings in the data with regard to our research questions. These analyses will be carried out using MAXQDA textual data analysis software. Verbatim citations will be used to illustrate tendencies, provide the phenomena of interest with context and aid in our in-depth understanding of COVID-19's impacts on older adult nursing home residents.

We will draw up tables describing the absolute and relative frequencies of item responses. The reliability and validity of constructs will be ensured by the detailed documentation maintained in investigators' field notes at each stage of the research. The study's internal validity will be ensured by triangulating data from multiple sources. The validity of external data will be ensured by selecting several subjects over the course of the study, using purposive sampling to provide a diverse subject set until data saturation.

Integrating quantitative and qualitative data

The integration of the study's quantitative and qualitative elements will occur jointly at the data interpretation stage. This will be based upon the treatment of the quantitative data from our sociodemographic and clinical questionnaires and from the treatment of our qualitative data from our interviews with residents, their relatives and their healthcare and support professionals and the research team's field notes:

- We will describe the stressors reported by residents and their relatives who present with high and low scores on the GHQ-12, IES-6, WHOQOL-BREF or WHOQOL-OLD, PSS and PTGI-SP scales.
- Data integration will provide us with information about the links between the stressors experienced by residents and their relatives and the consequences on their health.

- We will describe the coping strategies used by residents and their relatives who present with high and low scores on the GHQ-12, IES-6, PSS, WHOQOL-BREF or WHOQOL_OLD and PTGI-SP. This integration will provide us with information about the relative effectiveness of some of their coping strategies with regards to others.
- We will compare residents' and their relatives' reported frequency of use of the different coping strategies measured in the Brief Coping scale. Integrating this information will deepen our understanding of the coping strategies implemented by residents and their relatives during the pandemic.
- We will describe the stressors that healthcare and support professionals perceived residents and their relatives were facing. Integrating this information will help us to evaluate residents' and their relatives' needs and whether those needs were considered or not.
- We will compare the coping strategies reported by residents and their relatives with those support interventions actually put into practice by healthcare and support professionals. Integrating this information will help us understand how appropriate the support provided by healthcare and support professionals actually was, how different support measures complemented each other and where support was lacking.

In summary, putting our questionnaires findings into perspective regarding the health statuses of residents and their relatives and the results from our interviews will help us to identify their needs in terms of the preventive health interventions that could be developed to optimally maintain their health in the ongoing COVID-19 pandemic or a future one. The results from the focus group discussions involving healthcare and support professionals will help us to specify priority interventions that currently do not exist.

Study status

The present study began on 1 January 2021 and is planned to finish on 31 December 2022. Data collection began on 1 April 2021 because of the evolving epidemic situation in Switzerland, and collection is set to finish on 28 February 2023.

Discussion

The present exploratory study will contribute to a greater understanding of nursing home residents' and their relatives' lived experiences of COVID-19, the strategies they employed to cope with the pandemic and the consequences of those strategies. This will provide valuable knowledge about the epidemic's effects on this vulnerable and severely affected population. The study will provide essential data on the perceptions residents and their relatives had about their psychological health soon after the stage of strict lockdown, but also about the stressors to which they were exposed, the coping strategies they attempted to put in place and the results of those strategies. Our data should reveal the different types of stressors stemming from an epidemic situation in Switzerland's nursing homes as well as the adaptations and changes made to the processes of support provided to residents and their relatives. Exploring the results of residents' and relatives' strategies will allow us to assess them and formulate appropriate preventive-care interventions that will ensure the quality and safety of care for nursing home residents in case of future severe public health crises. It will also give indicators on how to protect their health and that of their relatives. New approaches could contribute to mitigating the impact of future pandemics and the consequences on the health of older adults living in nursing homes and their relatives. Furthermore, our findings could help to prioritise the development of preventive health interventions to counteract the effects of prolonged lockdowns for both of those groups. Our study considers the points of view of the diverse actors involved, which is essential when developing, testing and implementing new care practices. Its findings will provide the deeper understandings of patients' contexts and settings that are essential for anchoring changes in clinical practice, collaboration with relatives, training for healthcare professionals and managing nursing homes in general.

Ethics and dissemination

This project was approved by the Human Research Ethics Committee of the Canton of Vaud on 14 December 2020 (Project-ID: 2020-02397). The prior written informed consent of the study subjects is collected by a member of the research team before data collection. Major change to the study protocol will be announced to the Human Research Ethics Committee of the Canton of Vaud.

All the data collected is coded and kept securely at La Source School of Nursing. When dealing with quantitative data, each participant will be attributed an anonymous administrative code. Data will be installed on an SRP directory on La Source School of Nursing's server, which is housed in a data centre in Switzerland.

All interviews are audio-recorded in full. When this qualitative data is transcribed verbatim onto a Word 365 ProPlus® file, each participant is attributed an anonymous administrative code instead of their name. Residents' codes begin with the letters 'RES' and the letter 'Q' for qualitative data, followed by a two-digit number, starting with RESQ01 for the first resident interviewed and so on in chronological order. The same system is followed with relatives (e.g. RELQ04) and healthcare professionals (e.g. PROQ12).

All the participants are free to withdraw from the study at any moment without incurring any penalties or consequences with regards to the future care or services they might rightfully expect. Should a participant decide to withdraw, for whatever reason or at whatever moment, any data that have already been anonymised will not be destroyed but rather will still be analysed as specified in the research information sheet. Results will be presented in an aggregated form so that no participants will be identifiable in lectures or publications.

Only the principal investigator will have access to the key linking participants' codes to their names and identities, and this will only be used if absolutely necessary. All other researchers working on the study will only have access to coded data. The file containing the key to participants anonymity will be protected by a password known only to the principal investigator.

Data and material will be available on request from the authors.

Patient and public involvement

Patients and/or the public were not involved in the design or conduct of this research. Refer to the Methods and analysis section for further details.

Dissemination of results

Our results will be disseminated in various ways. A document containing the key facts will be prepared specifically for the participating care homes and other care homes on request. Public conferences will also be organised in those institutions. Scientific manuscripts will be addressed to international and French-language professional and scientific journals for publication. We will also disseminate our results at appropriate local and international conferences. Finally, a research report containing the study's highlights and most important findings will be produced for the libraries of our institutional partners and all the actors that participated financially in our work. Authorship will be defined using recommendations of the International Committee of Medical Journal Editors.

Author contributions

COB is the principal investigator. COB, MA, LB and CC contributed to the study design. MA, LB and CC are collecting the data. All authors are responsible for the data analyses. All authors read and approved the final manuscript.

Funding statement

This work is supported by the Grant for internal research project, University of Applied Sciences and Arts Western Switzerland, grant number: 09-O20.

Competing interests (for all authors)

The authors have no conflict of interest to declare.

References

1. Lum LHW, Tambyah PA. Outbreak of COVID-19 - an urgent need for good science to silence our fears? *Singapore Med J*. 2020;61(2):55-7.
2. Sim K, Chua HC. The psychological impact of SARS: a matter of heart and mind. *Canadian Medical Association Journal*. 2004;170(5):811-2.
3. Taha S, Matheson K, Cronin T, Anisman H. Intolerance of uncertainty, appraisals, coping, and anxiety: the case of the 2009 H1N1 pandemic. *Br J Health Psychol*. 2014;19(3):592-605.
4. Sim K, Huak Chan Y, Chong PN, Chua HC, Wen Soon S. Psychosocial and coping responses within the community health care setting towards a national outbreak of an infectious disease. *J Psychosom Res*. 2010;68(2):195-202.
5. Lee TM, Chi I, Chung LW, Chou KL. Ageing and psychological response during the post-SARS period. *Aging Ment Health*. 2006;10(3):303-11.
6. James PB, Wardle J, Steel A, Adams J. Post-Ebola psychosocial experiences and coping mechanisms among Ebola survivors: a systematic review. *Tropical Medicine & International Health*. 2019;24(6):671-91.
7. Moser A, Carlander M, Wieser S, Hämmig O, Puhan MA, Höglinger M. The COVID-19 Social Monitor longitudinal online panel: Real-time monitoring of social and public health consequences of the COVID-19 emergency in Switzerland. *PLoS One*. 2020;15(11):e0242129.
8. Vahia IV, Blazer DG, Smith GS, Karp JF, Steffens DC, Forester BP, et al. COVID-19, mental health and aging: A need for new knowledge to bridge science and service. *Am J Geriatr Psychiatry*. 2020;S1064-7481(20):30271-2.
9. Gardner W, States D, Bagley N. The Coronavirus and the risks to the elderly in long-term care. *J Aging Soc Policy*. 2020:1-6.
10. Fontannaz C. Inquiétude dans les EMS romands qui paient un lourd tribut au Covid-19 2020 [Available from: <https://www.rts.ch/info/regions/11220799-inquietude-dans-les-ems-romands-qui-paient-un-lourd-tribut-au-covid-19.html>].
11. DSAS. Directive concernant les mesures d'accompagnement des EMS et les modalités d'admissions en EMS pendant la phase de lutte contre le coronavirus COVID-19 In: Département de la Santé et de l'Action Sociale CdV, editor. 2020.
12. Brooke J, Jackson D. Older people and COVID-19: Isolation, risk and ageism. *J Clin Nurs*. 2020.
13. Keeley G. Corpses of the elderly found abandoned in Spanish care homes 2020 [Available from: <https://www.aljazeera.com/news/2020/03/corpses-elderly-abandoned-spanish-care-homes-200324141255435.html>].
14. Wirth T. Wacht auf, liebe Senioren! : *Tages Anzeiger*; 2020 [Available from: <https://www.tagesanzeiger.ch/wacht-auf-liebe-senioren-648625920236>].
15. Sparks H. Morbid "boomer remover" coronavirus meme only makes millennials seem more awful: *New York Post*; 2020 [Available from: <https://nypost.com/2020/03/19/morbid-boomer-remover-coronavirus-meme-only-makes-millennials-seem-more-awful/>].
16. Haffower H. A certain horrible subset of the internet is calling the coronavirus "boomer remover": *Business Insider Australia*; 2020 [Available from: <https://www.businessinsider.com/millennials-gen-z-calling-coronavirus-boomer-remover-reddit-2020-3?r=US&IR=T>].
17. Rabelo I, Lee V, Fallah MP, Massaquoi M, Evlampidou I, Crestani R, et al. Psychological distress among Ebola survivors discharged from an Ebola treatment unit in Monrovia, Liberia - A qualitative study. *Front Public Health*. 2016;4:142.

18. Schwerdtle PM, De Clerck V, Plummer V. Experiences of Ebola survivors: causes of distress and sources of resilience. *Prehosp Disaster Med.* 2017;32(3):234-9.
19. Dodgson JE, Tarrant M, Chee YO, Watkins A. New mothers' experiences of social disruption and isolation during the severe acute respiratory syndrome outbreak in Hong Kong. *Nurs Health Sci.* 2010;12(2):198-204.
20. Perrin PC, McCabe OL, Everly GS, Jr., Links JM. Preparing for an influenza pandemic: mental health considerations. *Prehosp Disaster Med.* 2009;24(3):223-30.
21. Mok E, Chung BP, Chung JW, Wong TK. An exploratory study of nurses suffering from severe acute respiratory syndrome (SARS). *Int J Nurs Pract.* 2005;11(4):150-60.
22. Bai Y, Lin CC, Lin CY, Chen JY, Chue CM, Chou P. Survey of stress reactions among health care workers involved with the SARS outbreak. *Psychiatr Serv.* 2004;55(9):1055-7.
23. Hawryluck L, Gold WL, Robinson S, Pogorski S, Galea S, Styra R. SARS control and psychological effects of quarantine, Toronto, Canada. *Emerg Infect Dis.* 2004;10(7):1206-12.
24. Cava MA, Fay KE, Beanlands HJ, McCay EA, Wignall R. The experience of quarantine for individuals affected by SARS in Toronto. *Public Health Nurs.* 2005;22(5):398-406.
25. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet.* 2020;395(10227):912-20.
26. Desclaux A, Badji D, Ndione AG, Sow K. Accepted monitoring or endured quarantine? Ebola contacts' perceptions in Senegal. *Soc Sci Med.* 2017;178:38-45.
27. Santini ZI, Jose PE, York Cornwell E, Koyanagi A, Nielsen L, Hinrichsen C, et al. Social disconnectedness, perceived isolation, and symptoms of depression and anxiety among older Americans (NSHAP): a longitudinal mediation analysis. *The Lancet Public Health.* 2020;5(1):e62-e70.
28. Freedman A, Nicolle J. Social isolation and loneliness: the new geriatric giants. *Canadian Family Physician.* 2020;66(3):176.
29. Cheng SKW, Chong GHC, Chang SSY, Wong CW, Wong CSY, Wong MTP, et al. Adjustment to severe acute respiratory syndrome (SARS): Roles of appraisal and post-traumatic growth. *Psychology & Health.* 2006;21(3):301-17.
30. Cheng C, Wong WM, Tsang KW. Perception of benefits and costs during SARS outbreak: An 18-month prospective study. *J Consult Clin Psychol.* 2006;74(5):870-9.
31. Chiang HH, Chen MB, Sue IL. Self-state of nurses in caring for SARS survivors. *Nurs Ethics.* 2007;14(1):18-26.
32. Neuman B, Fawcett J. *The Neuman Systems Model.* 5th ed. Education P, editor. New-York: Pearson Education; 2011.
33. Neuman B, Fawcett J. *The Neuman Systems Model,* 5th ed. Upper Saddle River, NJ: Pearson; 2011.
34. Creswell JW, Creswell JD. *Research design: Qualitative, quantitative, and mixed methods approaches.* Los Angeles: Sage Publications; 2018.
35. Fortin M-F, Gagnon J. *Fondements et étapes du processus de recherche : méthodes quantitatives et qualitatives (3e ed.).* Montréal: Chenelière Education; 2016.
36. Larivière N, Corbière M. *Méthodes qualitatives, quantitatives et mixtes : dans la recherche en sciences humaines dans la recherche en sciences humaines, sociales et de la santé.* Québec: Presses de l'Université du Québec; 2014.
37. Leplège A, Perret-Guillaume C, Ecosse E, Hervy MP, Ankri J, von Steinbüchel N. Un nouvel instrument destiné à mesurer la qualité de vie des résidents : le WHOQOL-OLD version française. *La Revue de Médecine Interne.* 2013;34(2):78-84.
38. Weiss D, Marmar C. The impact of event scale – revised. In: Wilson J, Keane T, editors. *Assessing psychological trauma and PTSD.* New York: Guilford Press; 1997. p. 399–411.
39. Tedeschi RG, Calhoun LG. The Posttraumatic Growth Inventory: Measuring the positive legacy of trauma. *Journal of Traumatic Stress.* 1996;9(3):455-71.
40. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav.* 1983;24(4):385-96.

1
2 41. Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically based
3 approach. *J Pers Soc Psychol.* 1989;56(2):267-83.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Page 2
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Page.2
	2b	All items from the World Health Organization Trial Registration Data Set	NA
Protocol version	3	Date and version identifier	Page 2
Funding	4	Sources and types of financial, material, and other support	Page 3, par. 2
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	Page 1 Page 11, par 1
	5b	Name and contact information for the trial sponsor	Page 1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	NA
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	NA
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Pages 4-5
	6b	Explanation for choice of comparators	NA

1				
2	Objectives	7	Specific objectives or hypotheses	Page 5, par.5
3				
4	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	Page 6, par.1
5				
6				
7				
8				
9				
10	Methods: Participants, interventions, and outcomes			
11				
12	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Page 8, par 1
13				
14				
15				
16				
17	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Page 6, par 6
18				
19				
20				
21				
22				
23	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	NA
24				
25				
26				
27				
28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	NA
29				
30				
31				
32				
33		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	NA
34				
35				
36				
37				
38		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	NA
39				
40				
41	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Page 7, par 1-2 Page 8, par 3-4
42				
43				
44				
45				
46				
47				
48				
49				
50	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	NA
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1				
2	Sample size	14	Estimated number of participants needed to achieve	Page 6, par 7
3			study objectives and how it was determined, including	
4			clinical and statistical assumptions supporting any	
5			sample size calculations	
6				
7	Recruitment	15	Strategies for achieving adequate participant enrolment	Page 6, par 7
8			to reach target sample size	
9				

Methods: Assignment of interventions (for controlled trials)

Allocation:

14	Sequence	16a	Method of generating the allocation sequence (eg,	NA
15	generation		computer-generated random numbers), and list of any	
16			factors for stratification. To reduce predictability of a	
17			random sequence, details of any planned restriction	
18			(eg, blocking) should be provided in a separate	
19			document that is unavailable to those who enrol	
20			participants or assign interventions	
21				
22				
23				
24	Allocation	16b	Mechanism of implementing the allocation sequence	NA
25	concealment		(eg, central telephone; sequentially numbered, opaque,	
26	mechanism		sealed envelopes), describing any steps to conceal the	
27			sequence until interventions are assigned	
28				
29				
30	Implementation	16c	Who will generate the allocation sequence, who will	NA
31			enrol participants, and who will assign participants to	
32			interventions	
33				
34	Blinding	17a	Who will be blinded after assignment to interventions	NA
35	(masking)		(eg, trial participants, care providers, outcome	
36			assessors, data analysts), and how	
37				
38				
39		17b	If blinded, circumstances under which unblinding is	NA
40			permissible, and procedure for revealing a participant's	
41			allocated intervention during the trial	
42				

Methods: Data collection, management, and analysis

45	Data collection	18a	Plans for assessment and collection of outcome,	Page 6, par 2
46	methods		baseline, and other trial data, including any related	Page 7, par 3
47			processes to promote data quality (eg, duplicate	
48			measurements, training of assessors) and a description	
49			of study instruments (eg, questionnaires, laboratory	
50			tests) along with their reliability and validity, if known.	
51			Reference to where data collection forms can be found,	
52			if not in the protocol	
53				
54				
55				
56		18b	Plans to promote participant retention and complete	NA
57			follow-up, including list of any outcome data to be	
58			collected for participants who discontinue or deviate	
59			from intervention protocols	
60				

1				
2	Data	19	Plans for data entry, coding, security, and storage,	Page 10, par. 4
3	management		including any related processes to promote data quality	
4			(eg, double data entry; range checks for data values).	
5			Reference to where details of data management	
6			procedures can be found, if not in the protocol	
7				
8	Statistical	20a	Statistical methods for analysing primary and	Page 7, par 2
9	methods		secondary outcomes. Reference to where other details	Page 8, par 4/6-8
10			of the statistical analysis plan can be found, if not in the	
11			protocol	
12				
13				
14		20b	Methods for any additional analyses (eg, subgroup and	NA
15			adjusted analyses)	
16				
17		20c	Definition of analysis population relating to protocol	Page 7, par 2
18			non-adherence (eg, as randomised analysis), and any	
19			statistical methods to handle missing data (eg, multiple	
20			imputation)	
21				
22				
23	Methods: Monitoring			
24				
25	Data monitoring	21a	Composition of data monitoring committee (DMC);	NA
26			summary of its role and reporting structure; statement	
27			of whether it is independent from the sponsor and	
28			competing interests; and reference to where further	
29			details about its charter can be found, if not in the	
30			protocol. Alternatively, an explanation of why a DMC is	
31			not needed	
32				
33				
34		21b	Description of any interim analyses and stopping	NA
35			guidelines, including who will have access to these	
36			interim results and make the final decision to terminate	
37			the trial	
38				
39				
40	Harms	22	Plans for collecting, assessing, reporting, and	NA
41			managing solicited and spontaneously reported	
42			adverse events and other unintended effects of trial	
43			interventions or trial conduct	
44				
45				
46	Auditing	23	Frequency and procedures for auditing trial conduct, if	NA
47			any, and whether the process will be independent from	
48			investigators and the sponsor	
49				
50				
51	Ethics and dissemination			
52				
53	Research ethics	24	Plans for seeking research ethics	Page 10, par 2
54	approval		committee/institutional review board (REC/IRB)	
55			approval	
56				
57				
58				
59				
60				

1				
2	Protocol	25	Plans for communicating important protocol	Page 10, par 2
3	amendments		modifications (eg, changes to eligibility criteria,	
4			outcomes, analyses) to relevant parties (eg,	
5			investigators, REC/IRBs, trial participants, trial	
6			registries, journals, regulators)	
7				
8				
9	Consent or assent	26a	Who will obtain informed consent or assent from	Page 10, par 2
10			potential trial participants or authorised surrogates, and	
11			how (see Item 32)	
12				
13		26b	Additional consent provisions for collection and use of	NA
14			participant data and biological specimens in ancillary	
15			studies, if applicable	
16				
17	Confidentiality	27	How personal information about potential and enrolled	Page 10, par 5
18			participants will be collected, shared, and maintained in	
19			order to protect confidentiality before, during, and after	
20			the trial	
21				
22				
23	Declaration of	28	Financial and other competing interests for principal	Page 11, par 4
24	interests		investigators for the overall trial and each study site	
25				
26	Access to data	29	Statement of who will have access to the final trial	Page 10, par 3
27			dataset, and disclosure of contractual agreements that	
28			limit such access for investigators	
29				
30				
31	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and	NA
32	post-trial care		for compensation to those who suffer harm from trial	
33			participation	
34				
35	Dissemination	31a	Plans for investigators and sponsor to communicate	Page 10, par 7
36	policy		trial results to participants, healthcare professionals, the	
37			public, and other relevant groups (eg, via publication,	
38			reporting in results databases, or other data sharing	
39			arrangements), including any publication restrictions	
40				
41				
42		31b	Authorship eligibility guidelines and any intended use of	NA
43			professional writers	
44				
45		31c	Plans, if any, for granting public access to the full	Page 11, par 7
46			protocol, participant-level dataset, and statistical code	
47				
48				
49	Appendices			
50				
51	Informed consent	32	Model consent form and other related documentation	NA
52	materials		given to participants and authorised surrogates	
53				
54	Biological	33	Plans for collection, laboratory evaluation, and storage	NA
55	specimens		of biological specimens for genetic or molecular	
56			analysis in the current trial and for future use in ancillary	
57			studies, if applicable	
58				
59				
60				

1 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013
2 Explanation & Elaboration for important clarification on the items. Amendments to the
3 protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT
4 Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)"
5 license.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

The health and coping strategies of nursing home residents and their relatives during the COVID-19 pandemic: a mixed-methods study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059262.R1
Article Type:	Protocol
Date Submitted by the Author:	23-Feb-2022
Complete List of Authors:	Ortoleva Bucher, Claudia; University of Applied Sciences Western Switzerland La Source School of Nursing Abt, Maryline; University of Applied Sciences Western Switzerland La Source School of Nursing Berthoud, Laurent; University of Applied Sciences Western Switzerland La Source School of Nursing Cohen, Christine; University of Applied Sciences Western Switzerland La Source School of Nursing
Primary Subject Heading:	Mental health
Secondary Subject Heading:	General practice / Family practice
Keywords:	COVID-19, MENTAL HEALTH, GENERAL MEDICINE (see Internal Medicine)

SCHOLARONE™
Manuscripts

1
2
3
4 Title Page
5

- 6
7 a) **Title:** The health and coping strategies of nursing home residents and their relatives during
8 the COVID-19 pandemic: a mixed-methods study protocol
9
10
11 b) **All authors' full names:** Claudia ORTOLEVA BUCHER, Maryline ABT, Laurent BERTHOUD,
12 Christine COHEN
13
14
15 c) **Corresponding author:** Claudia Ortoleva Bucher, HES-SO University of Applied Sciences and
16 Arts Western Switzerland, La Source School of Nursing Sciences, Avenue Vinet 30, 1004
17 Lausanne, Switzerland. ORCID ID: 0000-0002-8411-4181, E-mail:
18 c.ortolevabucher@ecolelasource.ch, Phone: +41 21 556 40 42
19
20
21
22 d) Claudia ORTOLEVA BUCHER: La Source School of Nursing Sciences, HES-SO University of
23 Applied Sciences and Arts Western Switzerland, La Source School of Nursing Sciences,
24 Avenue Vinet 30, 1004 Lausanne, Switzerland. ORCID ID: 0000-0002-8411-4181
25
26
27 Maryline ABT: La Source School of Nursing Sciences HES-SO University of Applied Sciences and
28 Arts Western Switzerland, La Source School of Nursing Sciences, Avenue Vinet 30, 1004
29 Lausanne, Switzerland. ORCID ID: 0000-0002-8867-951
30
31
32
33 Laurent BERTHOUD: La Source School of Nursing Sciences, HES-SO University of Applied
34 Sciences and Arts Western Switzerland, La Source School of Nursing Sciences, Avenue Vinet
35 30, 1004 Lausanne, Switzerland. ORCID ID: [0000-0002-6575-9101](https://orcid.org/0000-0002-6575-9101)
36
37
38 Christine COHEN: La Source School of Nursing Sciences, HES-SO University of Applied Sciences
39 and Arts Western Switzerland, La Source School of Nursing Sciences, Avenue Vinet 30, 1004
40 Lausanne, Switzerland. ORCID ID: [0000-0001-8681-0933](https://orcid.org/0000-0001-8681-0933)
41
42
43
44 e) **Keywords:** coping, nursing home residents, nursing home relatives, stressors, mixed-
45 methods, confinement measures, COVID-19 pandemic.
46
47
48 f) **No. of words:** 4240
49

50
51 La Source School of Nursing, University of Applied Sciences and Arts Western Switzerland
52 (HES-SO)

53
54 Avenue Vinet 30

55
56
57
58
59 Lausanne, CH 1004
60

1
2
3
4 **Title:** The health and coping strategies of nursing home residents and their relatives during the
5 COVID-19 pandemic: a mixed-methods study protocol
6
7

8
9
10 **Introduction:** The COVID-19 pandemic hit older adults particularly hard, especially those living in
11 nursing homes. The present study's primary aim is to quantify the states of physical and mental health
12 of nursing home residents and their relatives following the implementation of the exceptional
13 confinement measures. The secondary aim is to explore the lived experiences of the stressors
14 perceived by older adults and their relatives, as well as the support strategies implemented by health
15 professionals and their results.
16

17
18 **Methods and analysis:**

19 We chose a mixed-methods (quantitative/qualitative) study to best deliver a profound understanding
20 of this phenomenon.
21

22
23 Quantitative phase: Participants are asked to complete several questionnaires. The study population
24 includes all the nursing home residents in four French-speaking cantons of Switzerland (and their
25 relatives) who are living through the COVID-19 pandemic. Descriptive statistics will be calculated for
26 the scores of the GHQ-12, IES-6, PSS, Brief Cope, PTGI-SP, WHOQOL-BREF and WHOQOL-OLD scales.
27 Correlational analyses will be considered.
28

29
30 Qualitative phase: Data are collected from several sources (individual semi-structured interviews,
31 focus groups, field notes). Interviews are planned with about 12 representatives of each group of
32 participants (residents and relatives). Two focus groups made up of healthcare professionals will be
33 constituted to explore their perceptions of residents' and relatives' lived experiences of stressors, the
34 coping strategies those two groups implemented to deal with them. The interviews and focus groups
35 will be subjected to a thematic contents analysis.
36

37 Integrating the quantitative and qualitative data will take place jointly with data interpretation.
38

39 **Ethics and dissemination:** This project was approved by the Human Research Ethics Committee of the
40 Canton of Vaud on 14 December 2020 (Project-ID: 2020-02397). The prior written informed consent
41 of the study subjects is collected by a member of the research team before data collection. Study
42 results will be disseminated via professional and peer-reviewed publications.
43
44

45
46
47 **Trial registration:** ISRCTN12345167
48
49
50
51
52
53
54
55
56
57
58
59
60

STUDY STRENGTHS AND LIMITATIONS

- This study explores the lived experiences of nursing home residents and their relatives during the COVID-19 pandemic.
- Our research is framed within the concepts and processes of the Neuman systems model (2011)
- The psychometric qualities of the questionnaires and their suitability for the concepts under study ensure the validity of the data collected. Using a mixed-methods design facilitates a deep investigation of lived experiences.
- This study is limited because using a transversal methodology does not enable an investigation of changes over time.

INTRODUCTION

Lived experiences during epidemics affect communities' physical and psychological health (1). Indeed, just this century, we have had SARS in 2002–2003, H1N1 in 2009 and MERS in 2012 (2). The general population, including those not infected by the disease itself, still bears psychological scars (3-6). Older adults within that general population were also affected (5). Zurich University of Applied Sciences and the University of Zurich launched a study entitled "COVID-19 Social Monitor" among home-dwelling older adults, and its initial findings revealed that 41% of those questioned estimated that their overall quality of life (QoL) had deteriorated relative to before the pandemic, 50% presented with symptoms of psychological stress and exhaustion, and 9% suffered from loneliness (7). We sought to examine these issues among the residents of nursing homes caring for the very oldest people—those who often present with several comorbidities. Although this population has been the most vulnerable to the last 20 years' epidemics, the scientific research focus on it has been small (8). COVID-19 badly affected nursing homes in many countries when they became the centres of epidemic outbreaks (9). To date, half the deaths due to COVID-19 in French-speaking Switzerland have been in nursing homes (10). Drastic measures were taken to stem this grim tide, including physical isolation, one-way walking systems to reduce meetings, and bans on visiting (11).

Brooke and Jackson (12) have denounced the ageism that has clearly entered into public discourse since the beginning of the COVID-19 pandemic, mentioning some shocking reports about how nursing home residents were almost abandoned (13). Expressions of flagrant ageism have appeared and been rapidly amplified since the beginning of the pandemic, for example, under the hashtag #BoomerRemover, a nickname given to COVID-19. The coronavirus caused a resurgence of intergenerational conflict (14). Although some concerns were expressed about how older adults were being represented or positioned in this discourse, it was also often accompanied by unappreciative and disparaging language (15). Online discussions and comments about care rationing were also recurrent subjects of media attention, going so far as to suggest that the death of an old person was less important than that of a young one (16).

The people stigmatised and discriminated against (both COVID-19 survivors and members of the general population) have reported their feelings of abandonment and isolation (17-19).. Isolation is known to cause psychosocial problems and could affect any human being. Those already known to be vulnerable to them and particularly at risk of psychological harm include children and adolescents, nursing home residents, minority groups, people from socioeconomically disadvantaged groups, women and individuals suffering from pre-existing mental disorders (20). Even though people who are isolated or in quarantine understand the necessity of those measures, they nevertheless feel a sense of abandonment that can persist beyond those periods (21).. They can present with symptoms linked to acute stress disorders, irritability, sleeping disorders, emotional distress, mood disorders, depressive symptoms, fear and panic, anxiety, frustration and the boredom of solitude (22-26). Furthermore, longer periods of confinement have been associated with more severe symptoms of post-traumatic stress disorder, avoidance behaviours and greater feelings of anger (25). The longest periods of quarantine are particularly associated with increased symptoms of post-traumatic stress disorder, which may indicate that quarantine itself is lived as a traumatic experience (23).

Because of their inherent organisational characteristics and the strict confinement measures imposed on them during the pandemic, long-term residential care facilities generated stressors among their residents that the general population did not feel: isolation and solitude had particularly negative impacts on residents' physical and mental health, including their risks of anxiety, depression, cognitive dysfunction, heart diseases and mortality (27, 28). It should be noted that stress does not only lead to negative impacts. The strategies and processes put in place to cope with these enable individuals to change, adapt and appreciate their results. People can thus find the resources they need, experiment with different positive changes and grow out of their trauma (17, 21, 29-31).

1
2 The American Association for Geriatric Psychiatry has announced that it will support the scientific and
3 healthcare communities worldwide in order to help plan effective care for nursing home residents,
4 avoid the risks of this population becoming marginalised in political discussions surrounding COVID-19
5 and produce the greatest amount of valid, evidence-based data with which to orient more effective
6 care during this critical period (8).
7

8
9 Our research is framed within the concepts and processes of the Neuman systems model (2011), which
10 takes a holistic perspective oriented towards well-being. The model conceptualises the individual as
11 an open system subject to stressors that may or may not lead to damage to their health. Stressors are
12 considered neutral a priori, and their positive effects (eustress) or negative effects (distress) are largely
13 dependent on a person's perceptions and their capacity to face up to that stress. Following the
14 prolonged lockdown implemented towards the beginning of the COVID-19 pandemic, older adult
15 residents in nursing homes and their relatives were exposed to a variety of stressors susceptible of
16 destabilising them.
17

18 It is also essential to study the perceptions that healthcare and support professionals have of the lived
19 experiences of nursing home residents and their relatives. They are crucial to initiating any in-depth
20 evaluation of the effects of the internal and external stressors to which residents are exposed and their
21 capacity for coping with them (32, 33).
22

23 The main objective of this study is to evaluate the physical and mental health statuses of nursing home
24 residents and their relatives following the exceptional lockdown measures implemented due to the
25 COVID-19 epidemic. The secondary research objectives are the following:
26

- 27 - Describe the level of symptoms (post-traumatic stress, anxiety, depression, social
28 maladjustment and somatic disorders), post-traumatic growth and QoL of nursing home
29 residents and their relatives during the COVID-19 pandemic.
- 30 - Describe the strategies implemented (by residents and relatives) for coping with the COVID-
31 19 pandemic.
- 32 - Explore residents and relatives lived experiences of their perceived stressors during the COVID-
33 19 pandemic and their links to any potential physical or mental health symptoms, post-
34 traumatic growth and QoL.
- 35 - Explore which stressors healthcare and support professionals observed affecting residents and
36 their relatives.
- 37 - Explore which strategies healthcare and support professionals implemented to support
38 residents and their relatives and help them cope with the stressors they faced during the
39 COVID-19 pandemic, including their results.
40
41
42
43
44
45

46 **METHODS AND ANALYSIS**

47 **Study design overview**

48 This study is based on a mixed-methods (quantitative/qualitative) design chosen because there are
49 very few available data on nursing home residents. The variety and complexity of residents' health
50 statuses, the different living environments in their nursing homes and the changing relationships with
51 their relatives made us hypothesise that findings that might seem obvious or natural in Switzerland's
52 general population might not be readily transferable to our subjects without significant adjustments.
53 Using a mixed-methods study design would help us develop a deeper understanding of our
54 phenomenon of interest (34, 35).
55
56
57
58
59
60

Quantitative phase

Data collection

We use a paper questionnaire format to explore and respond to our research questions. We ensured that validated French-language versions of the questionnaires selected had the necessary psychometric qualities and that they were appropriate with regards to our study's concepts, thus safeguarding the validity of our recorded data.

Data collected from our participating nursing home residents come from several sources (36). In order to describe our sample, we decided to measure residents' sociodemographic variables (age, sex, marital status, year of entry into the nursing home) as well as those of their relatives (age, sex, marital status, relationship with the nursing home resident, current nature and frequency of contact with the resident).

We also collect data on the lockdown measures implemented in the participating older adults' nursing homes (residents isolated in their rooms, availability of communication tools such as tablet computers, preparation of screened visiting rooms, etc.).

Participants

Our potential study population includes all nursing home residents aged 65 years old or more and their relatives (spouses, children, siblings, friends, cousins) living through the COVID-19 experience in one of Switzerland's four majority French-speaking cantons.

We want to have as many people as possible so that the sample can be representative, which is why we chose a convenience sample. To do this, we set very broad inclusion criteria in order to recruit as many people as possible, bearing in mind that, unfortunately, we have to deal with the fact that some people have died in the meantime and that it is always complicated to enter a retirement home.

For residents, inclusion criteria are: being over 65 years old, being able to discern and being able to speak and understand French; and exclusion criteria are: the presence of major irreversible neurocognitive disorders. For relatives, inclusion criteria are: being able to discern and being able to speak and understand French; and there is no exclusion criteria. For healthcare professionals are: working on the unit for more than 3 months and to have a care relationship with the residents and the family member; and exclusion criteria are: being a temporary worker or a student.

Sample and recruitment

The recruitment procedure for our study's quantitative arm involves nursing home residents and their relatives. We aim for a sample of 150 residents and 150 relatives. This is done via the intermediary of care unit heads who identify residents susceptible of participating in our study because they fulfil our inclusion criteria. Investigators then visit the nursing homes and speak individually to potential subjects to inform them about the study. Residents are given time to reflect and to declare their consent to participate. A researcher then returns to sit with them while they complete their questionnaires. Relatives complete the questionnaires on their own.

Measurements

We use the following questionnaires to help us answer our research questions:

- The **General Health Questionnaire (GHQ-12, 12 items)** for detecting mental disorders in the general population (Cronbach's alpha: 0.91).
- The **WHOQOL-BREF scale (26 items)** for relatives to establish their subjective QoL (Cronbach's alpha: ≥ 0.65).

- The **WHOQOL-OLD scale (24 items)** for residents to evaluate their QoL (Cronbach's alpha: 0.72–0.83) (37).
- The **Impact of Event Scale 6 (IES-6, 6 items)** for measuring the symptoms associated with post-traumatic stress in individuals who have undergone a traumatic event (Cronbach's alpha: 0.95) (38).
- The **Post-traumatic Growth Inventory (PTGI-SP, 10 items)** for evaluating post-traumatic growth, i.e. positive, lived psychological change following a traumatic event (Cronbach's alpha: 0.90) (39).
- The **Perceived Stress Scale (PSS, 14 items)** for evaluating perceptions of stress (Cronbach's alpha: 0.74) (40).
- The **Brief Cope (28 items)** for evaluating coping strategies (Cronbach's alpha: 0.50–0.90) (41).

Analysis procedures for quantitative data

Data will be examined using Stata® statistical software, version 16. Data will first be cleaned, and if more than 10% of responses are missing from a particular scale, then that subject's observations will be discarded. Total scores and subscale scores for each questionnaire will be calculated following their authors' particular recommendations. For categorical or discrete variables, frequencies, percentages and modes will be calculated. For continuous variables, means, medians, standard deviations and interquartile ranges will be calculated. Skewness and kurtosis coefficients will be calculated to evaluate distributions and their normality. We will calculate descriptive statistics for the total scale scores and subscale scores of the GHQ-12, IES-6, PSS, Brief Cope, PTGI-SP, WHOQOL-BREF and WHOQOL-OLD scales. Finally, we will perform correlational analyses between the subscale scores for the GHQ-12, IES-6, PTGI-SP, WHOQOL-BREF and WHOQOL-OLD scales and the subscales scores of the Brief Cope scale.

Sociodemographic variables will be analysed using descriptive statistics depending on the variable measured.

Qualitative phase

Data collection

Qualitative data are collected from a number of sources (36):

- Individual, semi-structured, 20–30-minute interviews are carried out with **residents**, with the aid of an interview guide, to explore their perceptions of their lived experiences of stressors, the coping strategies that they implemented to deal with them and the results they obtained.
- Individual, semi-structured, 30–40-minute interviews are carried out with **relatives**, with the aid of an interview guide, to explore their perceptions of their lived experiences of stressors, the coping strategies that they implemented to deal with them and the results they obtained.
- Two 60–90-minute focus groups will be run with **nursing home professionals**, with the aid of an interview guide, to explore their perceptions of residents' and relatives' lived experiences of stressors, the coping strategies those two groups implemented to deal with them and the results they obtained.
- The research team keeps field notes about visits to nursing homes and during interviews. In particular, this information includes investigators' notes on participants' behaviours.

Participants

The nursing home residents and their relatives selected for this qualitative data collection phase are subject to the same selection criteria used in the quantitative data collection phase. The inclusion criteria for nursing home professionals are to have worked in the unit for at least three months and to

1
2 have regular contact with both residents and their relatives. Exclusion criteria include being a
3 temporary employee, a part-time employee, or a student.
4

5 **Sample and recruitment**

6
7 Participants are selected using purposive sampling to ensure representativity across several variables
8 (severity of symptoms, post-traumatic growth, QoL, varied coping strategies). Interviews are planned
9 with about 12 representatives of each group of participants (residents and relatives) or until data
10 saturation.
11

12
13 Two focus group discussion groups made up of healthcare professionals will be constituted to explore
14 their perceptions of residents' and relatives' lived experiences of stressors, the coping strategies those
15 two groups implemented to deal with them and what those strategies' results were. All the healthcare
16 professionals in our partner nursing homes will be invited to participate.
17

18 **Analysis procedures for qualitative data**

19
20 Data analysis began as soon as data collection began and continues iteratively. The interviews are
21 conducted in the nursing home in a place that respects the confidentiality of the exchange: in the
22 resident's room if he or she is alone or in an appropriate office for relatives. The interviews will be
23 conducted by the research assistant, who is a PhD nurse specializing in qualitative research. The
24 interviews will be audio-recorded and transferred to a secure server at the school. They will be
25 transcribed by a specialist company and the verbatims will be inserted into a Word 365 Pro plus[®] file.
26 The data will be subjected to a thematic content analysis inspired by the Neuman model. This means
27 that we will interpret the data by coding them according to this model. These analyses will be carried
28 out using MAXQDA textual data analysis software. Verbatim citations will be used to illustrate
29 tendencies, provide the phenomena of interest with context and aid in our in-depth understanding of
30 COVID-19's impacts on older adult nursing home residents.
31
32

33
34 We will draw up tables describing the absolute and relative frequencies of item responses. The
35 reliability and validity of constructs will be ensured by the detailed documentation maintained in
36 investigators' field notes at each stage of the research. The study's internal validity will be ensured by
37 triangulating data from multiple sources. The validity of external data will be ensured by selecting
38 several subjects over the course of the study, using purposive sampling to provide a diverse subject
39 set until data saturation.
40

41 **Integrating quantitative and qualitative data**

42
43 The integration of the study's quantitative and qualitative elements will occur jointly at the data
44 interpretation stage. This will be based upon the treatment of the quantitative data from our
45 sociodemographic and clinical questionnaires and from the treatment of our qualitative data from our
46 interviews with residents, their relatives and their healthcare and support professionals and the
47 research team's field notes:
48

- 49 - We will describe the stressors reported by residents and their relatives who present with high and
50 low scores on the GHQ-12, IES-6, WHOQOL-BREF or WHOQOL-OLD, PSS and PTGI-SP scales.
- 51 - Data integration will provide us with information about the links between the stressors experienced
52 by residents and their relatives and the consequences on their health.
- 53 - We will describe the coping strategies used by residents and their relatives who present with high
54 and low scores on the GHQ-12, IES-6, PSS, WHOQOL-BREF or WHOQOL_OLD and PTGI-SP. This
55 integration will provide us with information about the relative effectiveness of some of their coping
56 strategies with regards to others.
- 57 - We will compare residents' and their relatives' reported frequency of use of the different coping
58 strategies measured in the Brief Cope scale. Integrating this information will deepen our
59
60

1
2 understanding of the coping strategies implemented by residents and their relatives during the
3 pandemic.

- 4 - We will describe the stressors that healthcare and support professionals perceived residents and
5 their relatives were facing. Integrating this information will help us to evaluate residents' and their
6 relatives' needs and whether those needs were considered or not.
7
8 - We will compare the coping strategies reported by residents and their relatives with those support
9 interventions actually put into practice by healthcare and support professionals. Integrating this
10 information will help us understand how appropriate the support provided by healthcare and
11 support professionals actually was, how different support measures complemented each other and
12 where support was lacking.
13
14

15 In summary, putting our questionnaires findings into perspective regarding the health statuses of
16 residents and their relatives and the results from our interviews will help us to identify their needs in
17 terms of the preventive health interventions that could be developed to optimally maintain their
18 health in the ongoing COVID-19 pandemic or a future one. The results from the focus group discussions
19 involving healthcare and support professionals will help us to specify priority interventions that
20 currently do not exist.
21
22

23 **Study status**

24
25 The present study began on 1 January 2021 and is planned to finish on 31 December 2022. Data
26 collection began on 1 April 2021 because of the evolving epidemic situation in Switzerland, and
27 collection is set to finish on 28 February 2023.
28
29

30 **Discussion**

31 The present exploratory study will contribute to a greater understanding of nursing home residents'
32 and their relatives' lived experiences of COVID-19, the strategies they employed to cope with the
33 pandemic and the consequences of those strategies. This will provide valuable knowledge about the
34 epidemic's effects on this vulnerable and severely affected population. The study will provide essential
35 data on the perceptions residents and their relatives had about their psychological health soon after
36 the stage of strict lockdown, but also about the stressors to which they were exposed, the coping
37 strategies they attempted to put in place and the results of those strategies. Our data should reveal
38 the different types of stressors stemming from an epidemic situation in Switzerland's nursing homes
39 as well as the adaptations and changes made to the processes of support provided to residents and
40 their relatives. Exploring the results of residents' and relatives' strategies will allow us to assess them
41 and formulate appropriate preventive-care interventions that will ensure the quality and safety of care
42 for nursing home residents in case of future severe public health crises. It will also give indicators on
43 how to protect their health and that of their relatives. New approaches could contribute to mitigating
44 the impact of future pandemics and the consequences on the health of older adults living in nursing
45 homes and their relatives. Furthermore, our findings could help to prioritise the development of
46 preventive health interventions to counteract the effects of prolonged lockdowns for both of those
47 groups. Our study considers the points of view of the diverse actors involved, which is essential when
48 developing, testing and implementing new care practices. Its findings will provide the deeper
49 understandings of patients' contexts and settings that are essential for anchoring changes in clinical
50 practice, collaboration with relatives, training for healthcare professionals and managing nursing
51 homes in general.
52
53
54
55
56

57 **Ethics and dissemination**

58
59 This project was approved by the Human Research Ethics Committee of the Canton of Vaud on 14
60 December 2020 (Project-ID: 2020-02397). The prior written informed consent of the study subjects is

1
2 collected by a member of the research team before data collection. Major change to the study protocol
3 will be announced to the Human Research Ethics Committee of the Canton of Vaud.
4

5 All the data collected is coded and kept securely at La Source School of Nursing. When dealing with
6 quantitative data, each participant will be attributed an anonymous administrative code. Data will be
7 installed on an SRP directory on La Source School of Nursing's server, which is housed in a data centre
8 in Switzerland.
9

10 All interviews are audio-recorded in full. When this qualitative data is transcribed verbatim onto a
11 Word 365 ProPlus® file, each participant is attributed an anonymous administrative code instead of
12 their name. Residents' codes begin with the letters 'RES' and the letter 'Q' for qualitative data, followed
13 by a two-digit number, starting with RESQ01 for the first resident interviewed and so on in
14 chronological order. The same system is followed with relatives (e.g. RELQ04) and healthcare
15 professionals (e.g. PROQ12).
16
17

18 All the participants are free to withdraw from the study at any moment without incurring any penalties
19 or consequences with regards to the future care or services they might rightfully expect. Should a
20 participant decide to withdraw, for whatever reason or at whatever moment, any data that have
21 already been anonymised will not be destroyed but rather will still be analysed as specified in the
22 research information sheet. Results will be presented in an aggregated form so that no participants
23 will be identifiable in lectures or publications.
24
25

26 Only the principal investigator will have access to the key linking participants' codes to their names
27 and identities, and this will only be used if absolutely necessary. All other researchers working on the
28 study will only have access to coded data. The file containing the key to participants anonymity will be
29 protected by a password known only to the principal investigator.
30

31 Data and material will be available on request from the authors.
32

33 ***Patient and public involvement***

34 Patients and/or the public were not involved in the design or conduct of this research. Refer to the
35 Methods and analysis section for further details.
36
37

38 ***Dissemination of results***

39 Our results will be disseminated in various ways. A document containing the key facts will be prepared
40 specifically for the participating care homes and other care homes on request. Public conferences will
41 also be organised in those institutions. Scientific manuscripts will be addressed to international and
42 French-language professional and scientific journals for publication. We will also disseminate our
43 results at appropriate local and international conferences. Finally, a research report containing the
44 study's highlights and most important findings will be produced for the libraries of our institutional
45 partners and all the actors that participated financially in our work. Authorship will be defined using
46 recommendations of the International Committee of Medical Journal Editors.
47
48

49 ***Author contributions***

50 COB is the principal investigator. COB, MA, LB and CC contributed to the study design. MA, LB and CC
51 are collecting the data. All authors are responsible for the data analyses. All authors read and approved
52 the final manuscript.
53

54 ***Funding statement***

55 This work is supported by the Grant for internal research project, University of Applied Sciences and
56 Arts Western Switzerland, grant number: 09-O20.
57
58

59 ***Competing interests (for all authors)***

60 The authors have no conflict of interest to declare.

References

1. Sim K, Chua HC. The psychological impact of SARS: a matter of heart and mind. *Canadian Medical Association Journal*. 2004;170(5):811-2.
2. Lum LHW, Tambyah PA. Outbreak of COVID-19 - an urgent need for good science to silence our fears? *Singapore Med J*. 2020;61(2):55-7.
3. Taha S, Matheson K, Cronin T, Anisman H. Intolerance of uncertainty, appraisals, coping, and anxiety: the case of the 2009 H1N1 pandemic. *Br J Health Psychol*. 2014;19(3):592-605.
4. Sim K, Huak Chan Y, Chong PN, Chua HC, Wen Soon S. Psychosocial and coping responses within the community health care setting towards a national outbreak of an infectious disease. *J Psychosom Res*. 2010;68(2):195-202.
5. Lee TM, Chi I, Chung LW, Chou KL. Ageing and psychological response during the post-SARS period. *Aging Ment Health*. 2006;10(3):303-11.
6. James PB, Wardle J, Steel A, Adams J. Post-Ebola psychosocial experiences and coping mechanisms among Ebola survivors: a systematic review. *Tropical Medicine & International Health*. 2019;24(6):671-91.
7. Moser A, Carlander M, Wieser S, Hämmig O, Puhon MA, Höglinger M. The COVID-19 Social Monitor longitudinal online panel: Real-time monitoring of social and public health consequences of the COVID-19 emergency in Switzerland. *PLoS One*. 2020;15(11):e0242129.
8. Vahia IV, Blazer DG, Smith GS, Karp JF, Steffens DC, Forester BP, et al. COVID-19, mental health and aging: A need for new knowledge to bridge science and service. *Am J Geriatr Psychiatry*. 2020;S1064-7481(20):30271-2.
9. Gardner W, States D, Bagley N. The Coronavirus and the risks to the elderly in long-term care. *J Aging Soc Policy*. 2020:1-6.
10. Fontannaz C. Inquiétude dans les EMS romands qui paient un lourd tribut au Covid-19 2020 [Available from: <https://www.rts.ch/info/regions/11220799-inquietude-dans-les-ems-romands-qui-paient-un-lourd-tribut-au-covid-19.html>].
11. DSAS. Directive concernant les mesures d'accompagnement des EMS et les modalités d'admissions en EMS pendant la phase de lutte contre le coronavirus COVID-19 In: Département de la Santé et de l'Action Sociale CdV, editor. 2020.
12. Brooke J, Jackson D. Older people and COVID-19: Isolation, risk and ageism. *J Clin Nurs*. 2020.
13. Keeley G. Corpses of the elderly found abandoned in Spanish care homes 2020 [Available from: <https://www.aljazeera.com/news/2020/03/corpses-elderly-abandoned-spanish-care-homes-200324141255435.html>].
14. Wirth T. Wacht auf, liebe Senioren! : *Tages Anzeiger*; 2020 [Available from: <https://www.tagesanzeiger.ch/wacht-auf-liebe-senioren-648625920236>].
15. Sparks H. Morbid "boomer remover" coronavirus meme only makes millennials seem more awful: *New York Post*; 2020 [Available from: <https://nypost.com/2020/03/19/morbid-boomer-remover-coronavirus-meme-only-makes-millennials-seem-more-awful/>].
16. Haffower H. A certain horrible subset of the internet is calling the coronavirus "boomer remover": *Business Insider Australia*; 2020 [Available from: <https://www.businessinsider.com/millennials-gen-z-calling-coronavirus-boomer-remover-reddit-2020-3?r=US&IR=T>].
17. Rabelo I, Lee V, Fallah MP, Massaquoi M, Evlampidou I, Crestani R, et al. Psychological distress among Ebola survivors discharged from an Ebola treatment unit in Monrovia, Liberia - A qualitative study. *Front Public Health*. 2016;4:142.
18. Schwerdtle PM, De Clerck V, Plummer V. Experiences of Ebola survivors: causes of distress and sources of resilience. *Prehosp Disaster Med*. 2017;32(3):234-9.
19. Dodgson JE, Tarrant M, Chee YO, Watkins A. New mothers' experiences of social disruption and isolation during the severe acute respiratory syndrome outbreak in Hong Kong. *Nurs Health Sci*. 2010;12(2):198-204.
20. Perrin PC, McCabe OL, Everly GS, Jr., Links JM. Preparing for an influenza pandemic: mental health considerations. *Prehosp Disaster Med*. 2009;24(3):223-30.
21. Mok E, Chung BP, Chung JW, Wong TK. An exploratory study of nurses suffering from severe acute respiratory syndrome (SARS). *Int J Nurs Pract*. 2005;11(4):150-60.

22. Bai Y, Lin CC, Lin CY, Chen JY, Chue CM, Chou P. Survey of stress reactions among health care workers involved with the SARS outbreak. *Psychiatr Serv.* 2004;55(9):1055-7.
23. Hawryluck L, Gold WL, Robinson S, Pogorski S, Galea S, Styra R. SARS control and psychological effects of quarantine, Toronto, Canada. *Emerg Infect Dis.* 2004;10(7):1206-12.
24. Cava MA, Fay KE, Beanlands HJ, McCay EA, Wignall R. The experience of quarantine for individuals affected by SARS in Toronto. *Public Health Nurs.* 2005;22(5):398-406.
25. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet.* 2020;395(10227):912-20.
26. Desclaux A, Badji D, Ndione AG, Sow K. Accepted monitoring or endured quarantine? Ebola contacts' perceptions in Senegal. *Soc Sci Med.* 2017;178:38-45.
27. Santini ZI, Jose PE, York Cornwell E, Koyanagi A, Nielsen L, Hinrichsen C, et al. Social disconnectedness, perceived isolation, and symptoms of depression and anxiety among older Americans (NSHAP): a longitudinal mediation analysis. *The Lancet Public Health.* 2020;5(1):e62-e70.
28. Freedman A, Nicolle J. Social isolation and loneliness: the new geriatric giants. *Canadian Family Physician.* 2020;66(3):176.
29. Cheng SKW, Chong GHC, Chang SSSY, Wong CW, Wong CSY, Wong MTP, et al. Adjustment to severe acute respiratory syndrome (SARS): Roles of appraisal and post-traumatic growth. *Psychology & Health.* 2006;21(3):301-17.
30. Cheng C, Wong WM, Tsang KW. Perception of benefits and costs during SARS outbreak: An 18-month prospective study. *J Consult Clin Psychol.* 2006;74(5):870-9.
31. Chiang HH, Chen MB, Sue IL. Self-state of nurses in caring for SARS survivors. *Nurs Ethics.* 2007;14(1):18-26.
32. Neuman B, Fawcett J. *The Neuman Systems Model.* 5th ed. Education P, editor. New-York: Pearson Education; 2011.
33. Neuman B, Fawcett J. *The Neuman Systems Model,* 5th ed. Upper Saddle River, NJ: Pearson; 2011.
34. Creswell JW, Creswell JD. *Research design: Qualitative, quantitative, and mixed methods approaches.* Los Angeles: Sage Publications; 2018.
35. Fortin M-F, Gagnon J. *Fondements et étapes du processus de recherche : méthodes quantitatives et qualitatives (3e ed.).* Montréal: Chenelière Education; 2016.
36. Larivière N, Corbière M. *Méthodes qualitatives, quantitatives et mixtes : dans la recherche en sciences humaines dans la recherche en sciences humaines, sociales et de la santé.* Québec: Presses de l'Université du Québec; 2014.
37. Leplège A, Perret-Guillaume C, Ecosse E, Hervy MP, Ankri J, von Steinbüchel N. Un nouvel instrument destiné à mesurer la qualité de vie des personnes âgées : le WHOQOL-OLD version française. *La Revue de Médecine Interne.* 2013;34(2):78-84.
38. Weiss D, Marmar C. The impact of event scale – revised. In: Wilson J, Keane T, editors. *Assessing psychological trauma and PTSD.* New York: Guilford Press; 1997. p. 399–411.
39. Tedeschi RG, Calhoun LG. The Posttraumatic Growth Inventory: Measuring the positive legacy of trauma. *Journal of Traumatic Stress.* 1996;9(3):455-71.
40. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav.* 1983;24(4):385-96.
41. Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically based approach. *J Pers Soc Psychol.* 1989;56(2):267-83.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Page 2
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Page.2
	2b	All items from the World Health Organization Trial Registration Data Set	NA
Protocol version	3	Date and version identifier	Page 2
Funding	4	Sources and types of financial, material, and other support	Page 3, par. 2
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	Page 1 Page 11, par 1
	5b	Name and contact information for the trial sponsor	Page 1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	NA
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	NA
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Pages 4-5
	6b	Explanation for choice of comparators	NA

1				
2	Objectives	7	Specific objectives or hypotheses	Page 5, par.5
3				
4	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	Page 6, par.1
5				
6				
7				
8				
9				
10	Methods: Participants, interventions, and outcomes			
11				
12	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Page 8, par 1
13				
14				
15				
16				
17	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Page 6, par 6
18				
19				
20				
21				
22				
23	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	NA
24				
25				
26				
27				
28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	NA
29				
30				
31				
32				
33		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	NA
34				
35				
36				
37				
38		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	NA
39				
40				
41	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Page 7, par 1-2 Page 8, par 3-4
42				
43				
44				
45				
46				
47				
48				
49				
50	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	NA
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1				
2	Sample size	14	Estimated number of participants needed to achieve	Page 6, par 7
3			study objectives and how it was determined, including	
4			clinical and statistical assumptions supporting any	
5			sample size calculations	
6				
7	Recruitment	15	Strategies for achieving adequate participant enrolment	Page 6, par 7
8			to reach target sample size	
9				

Methods: Assignment of interventions (for controlled trials)

Allocation:

14	Sequence	16a	Method of generating the allocation sequence (eg,	NA
15	generation		computer-generated random numbers), and list of any	
16			factors for stratification. To reduce predictability of a	
17			random sequence, details of any planned restriction	
18			(eg, blocking) should be provided in a separate	
19			document that is unavailable to those who enrol	
20			participants or assign interventions	
21				
22				
23				
24	Allocation	16b	Mechanism of implementing the allocation sequence	NA
25	concealment		(eg, central telephone; sequentially numbered, opaque,	
26	mechanism		sealed envelopes), describing any steps to conceal the	
27			sequence until interventions are assigned	
28				
29				
30	Implementation	16c	Who will generate the allocation sequence, who will	NA
31			enrol participants, and who will assign participants to	
32			interventions	
33				
34	Blinding	17a	Who will be blinded after assignment to interventions	NA
35	(masking)		(eg, trial participants, care providers, outcome	
36			assessors, data analysts), and how	
37				
38				
39		17b	If blinded, circumstances under which unblinding is	NA
40			permissible, and procedure for revealing a participant's	
41			allocated intervention during the trial	
42				

Methods: Data collection, management, and analysis

45	Data collection	18a	Plans for assessment and collection of outcome,	Page 6, par 2
46	methods		baseline, and other trial data, including any related	Page 7, par 3
47			processes to promote data quality (eg, duplicate	
48			measurements, training of assessors) and a description	
49			of study instruments (eg, questionnaires, laboratory	
50			tests) along with their reliability and validity, if known.	
51			Reference to where data collection forms can be found,	
52			if not in the protocol	
53				
54				
55				
56		18b	Plans to promote participant retention and complete	NA
57			follow-up, including list of any outcome data to be	
58			collected for participants who discontinue or deviate	
59			from intervention protocols	
60				

1				
2	Data	19	Plans for data entry, coding, security, and storage,	Page 10, par. 4
3	management		including any related processes to promote data quality	
4			(eg, double data entry; range checks for data values).	
5			Reference to where details of data management	
6			procedures can be found, if not in the protocol	
7				
8	Statistical	20a	Statistical methods for analysing primary and	Page 7, par 2
9	methods		secondary outcomes. Reference to where other details	Page 8, par 4/6-8
10			of the statistical analysis plan can be found, if not in the	
11			protocol	
12				
13		20b	Methods for any additional analyses (eg, subgroup and	NA
14			adjusted analyses)	
15				
16		20c	Definition of analysis population relating to protocol	Page 7, par 2
17			non-adherence (eg, as randomised analysis), and any	
18			statistical methods to handle missing data (eg, multiple	
19			imputation)	
20				
21				
22				

Methods: Monitoring

23				
24				
25	Data monitoring	21a	Composition of data monitoring committee (DMC);	NA
26			summary of its role and reporting structure; statement	
27			of whether it is independent from the sponsor and	
28			competing interests; and reference to where further	
29			details about its charter can be found, if not in the	
30			protocol. Alternatively, an explanation of why a DMC is	
31			not needed	
32				
33		21b	Description of any interim analyses and stopping	NA
34			guidelines, including who will have access to these	
35			interim results and make the final decision to terminate	
36			the trial	
37				
38				
39				
40	Harms	22	Plans for collecting, assessing, reporting, and	NA
41			managing solicited and spontaneously reported	
42			adverse events and other unintended effects of trial	
43			interventions or trial conduct	
44				
45				
46	Auditing	23	Frequency and procedures for auditing trial conduct, if	NA
47			any, and whether the process will be independent from	
48			investigators and the sponsor	
49				
50				

Ethics and dissemination

51				
52				
53	Research ethics	24	Plans for seeking research ethics	Page 10, par 2
54	approval		committee/institutional review board (REC/IRB)	
55			approval	
56				
57				
58				
59				
60				

1				
2	Protocol	25	Plans for communicating important protocol	Page 10, par 2
3	amendments		modifications (eg, changes to eligibility criteria,	
4			outcomes, analyses) to relevant parties (eg,	
5			investigators, REC/IRBs, trial participants, trial	
6			registries, journals, regulators)	
7				
8				
9	Consent or assent	26a	Who will obtain informed consent or assent from	Page 10, par 2
10			potential trial participants or authorised surrogates, and	
11			how (see Item 32)	
12				
13		26b	Additional consent provisions for collection and use of	NA
14			participant data and biological specimens in ancillary	
15			studies, if applicable	
16				
17	Confidentiality	27	How personal information about potential and enrolled	Page 10, par 5
18			participants will be collected, shared, and maintained in	
19			order to protect confidentiality before, during, and after	
20			the trial	
21				
22				
23	Declaration of	28	Financial and other competing interests for principal	Page 11, par 4
24	interests		investigators for the overall trial and each study site	
25				
26	Access to data	29	Statement of who will have access to the final trial	Page 10, par 3
27			dataset, and disclosure of contractual agreements that	
28			limit such access for investigators	
29				
30				
31	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and	NA
32	post-trial care		for compensation to those who suffer harm from trial	
33			participation	
34				
35	Dissemination	31a	Plans for investigators and sponsor to communicate	Page 10, par 7
36	policy		trial results to participants, healthcare professionals, the	
37			public, and other relevant groups (eg, via publication,	
38			reporting in results databases, or other data sharing	
39			arrangements), including any publication restrictions	
40				
41				
42		31b	Authorship eligibility guidelines and any intended use of	NA
43			professional writers	
44				
45		31c	Plans, if any, for granting public access to the full	Page 11, par 7
46			protocol, participant-level dataset, and statistical code	
47				
48				
49	Appendices			
50				
51	Informed consent	32	Model consent form and other related documentation	NA
52	materials		given to participants and authorised surrogates	
53				
54	Biological	33	Plans for collection, laboratory evaluation, and storage	NA
55	specimens		of biological specimens for genetic or molecular	
56			analysis in the current trial and for future use in ancillary	
57			studies, if applicable	
58				
59				
60				

1 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013
2 Explanation & Elaboration for important clarification on the items. Amendments to the
3 protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT
4 Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)"
5 license.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only